Ruxolitinib, the first FDA-approved JAK/STAT pathway inhibitor, successfully triggered tumor regression in preclinical mouse models; however, clinical trials of pancreatic adenocarcinoma (46), breast cancer (47), colorectal cancer (48), and lung cancer (49) showed s lack of efficacy and very limited or no overall survival benefit. Here, SOAT1 is linked to lung carcinoma.